Fig. 5
Effect of RUNX3 on osimertinib resistance in PC9 cells (a) Identification of the target genes of miR-130a-3p using miRDB, TargetScan, and miRTarBase databases. (b, c) Protein concentrations of RUNX3 in PC9 and PC9OR cells normalized with β-actin. (d) Protein concentrations of RUNX3 and β-actin in PC9 cells transfected with the negative control (NC) and the miR-130a-3p mimic (130a mimic). (e) Relative mRNA expressions of RUNX3 in PC9 cells transfected with NC and miR-130a-3p inhibitor (130a inhibitor). (f) Protein concentrations of RUNX3 and β-actin in PC9 and PC9OR cells transfected with the NC and the 130a inhibitor. (g) Relative mRNA expression of RUNX3 in PC9 cells transfected with NC and si-RUNX3. The RUNX3 mRNA levels were normalized using the glyceraldehyde-3-phosphate dehydrogenase concentrations relative to the levels in PC9 cells transfected with the NC (e, g). (h) Protein concentrations of RUNX3 and β-actin in PC9 cells transfected with si-RUNX3. (i) Viability of PC9 cells transfected with si-RUNX3 in the absence or presence of 1 µM osimertinib for 72 h. Data are presented as mean ± SEM (n = 3–6). *P < 0.05, compared with PC9 cells or NC. P-values were determined using Student’s t-test (c, e, g) or ANOVA with Tukey–Kramer (i). Original blots are presented in Supplementary Figures S4b-d. ANOVA, analysis of variance.
